Publications
Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 15534359
Bergsland EK. Update on clinical trials targeting vascular endothelial growth factor in cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2004. PMID: 15552622
Bergsland EK. Vascular endothelial growth factor as a therapeutic target in cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2004. PMID: 15552621
Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer. 2004. PMID: 15372473
Goldberg RM, Venook AP, Schilsky RL. Cetuximab in the treatment of colorectal cancer. Clinical advances in hematology & oncology : H&O. 2004. PMID: 16170891
Martinez-Mariño B, Shiboski S, Hecht FM, Kahn JO, Levy JA. Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART. AIDS (London, England). 2004. PMID: 15577620
Levy JA. Prospects for an AIDS vaccine: encourage innate immunity. AIDS (London, England). 2004. PMID: 15577631
Wang H, McCann FE, Gordan JD, Wu X, Raab M, Malik TH, Davis DM, Rudd CE. ADAP-SLP-76 binding differentially regulates supramolecular activation cluster (SMAC) formation relative to T cell-APC conjugation. The Journal of experimental medicine. 2004. PMID: 15477347
Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004. PMID: 15470214
Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004. PMID: 15468186
Allen GM, Shortall BP, Gemci T, Corcoran TE, Chigier NA. Computational simulations of airflow in an in vitro model of the pediatric upper airways. Journal of biomechanical engineering. 2004. PMID: 15648813
Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB. Factors influencing the titer and infectivity of lentiviral vectors. Human gene therapy. 2004. PMID: 15585113
Allen J, Bergsland EK. Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematology/oncology clinics of North America. 2004. PMID: 15474337
Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Molecular and cellular biology. 2004. PMID: 15367669
Whisenant J, Venook A. Regional therapy of liver metastases. Current treatment options in oncology. 2004. PMID: 15341680
Tindall D, Horne FM, Hruszkewycz A, Mohla S, Shuman M, Wang Z, Kantoff P. Symposium on androgen action in prostate cancer. Cancer research. 2004. PMID: 15466216
Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nature reviews. Cancer. 2004. PMID: 15510162
Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO reports. 2004. PMID: 15359272
Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2004. PMID: 15345592
Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urologic oncology. 2004. PMID: 15464920